Moreover, other launched treatments for moderate-to-severe asthma such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab) and anti-IL-4/anti-IL-13 neutralizing antibodies (IL-4R; dupilumab), Singulair (leukotriene B4 receptor antagonist) and oral corticosteroids and pipeline products such as anti-TSLP and anti-IL-33 neutralizing antibodies did not reduce pulmonary neutrophilia, IL-17 and IL-8 to the same extent as RORγt blockade suggesting that a RORγt inhibitor will provide a unique mode of treatment for patients. Here, IL17A is linked to asthma.